Cryptocurrency News: XRP Validators, Malta, and Practical Tokens

Cryptocurrency News & Market Summary
Investors finally saw some light at the end of the tunnel last week, with cryptos soaring across the board. No one quite knows what kicked off the rally—as it could have been any of the stories we discuss below—but the net result was positive.

Of course, prices won’t stay on this rocket ride forever. I expect to see a resurgence of volatility in short order, because the market is moving as a single unit. Everything is rising in tandem.

This tells me that investors are simply “buying the dip” rather than identifying which cryptos have enough real-world value to outlive the crash.

So if you want to know when.

The post Cryptocurrency News: XRP Validators, Malta, and Practical Tokens appeared first on Profit Confidential.

Excerpt from:

Cryptocurrency News: XRP Validators, Malta, and Practical Tokens

Cryptocurrency News: What You Need to Know This Week

Cryptocurrency News
Cryptocurrencies traded sideways since our last report on cryptos. However, I noticed something interesting when playing around with Yahoo! Finance’s cryptocurrency screener: There are profitable pockets in this market.

Incidentally, Yahoo’s screener is far superior to the one on CoinMarketCap, so if you’re looking to compare digital assets, I highly recommend it.

But let's get back to my epiphany.

In the last month, at one point or another, most crypto assets on our favorites list saw double-digit increases. It’s true that each upswing was followed by a hard crash, but investors who rode the trend would have made a.

The post Cryptocurrency News: What You Need to Know This Week appeared first on Profit Confidential.

Original post:

Cryptocurrency News: What You Need to Know This Week

Cryptocurrency News: Vitalik Buterin Doesn’t Care About Bitcoin ETFs

Cryptocurrency News
While headline numbers look devastating this week, investors might take some solace in knowing that cryptocurrencies found their bottom at roughly $189.8 billion in market cap—that was the low point. Since then, investors put more than $20.0 billion back into the market.

During the rout, Ethereum broke below $300.00 and XRP fell below $0.30, marking yearly lows for both tokens. The same was true down the list of the top 100 biggest cryptos.

Altcoins took the brunt of the hit. BTC Dominance, which reveals how tightly investment is concentrated in Bitcoin, rose from 42.62% to 53.27% in just one month, showing that investors either fled altcoins at higher.

The post Cryptocurrency News: Vitalik Buterin Doesn’t Care About Bitcoin ETFs appeared first on Profit Confidential.

See more here:

Cryptocurrency News: Vitalik Buterin Doesn’t Care About Bitcoin ETFs

Cryptocurrency News: New Exchanges Could Boost Crypto Liquidity

Cryptocurrency News
Even though the cryptocurrency news was upbeat in recent days, the market tumbled after the U.S. Securities and Exchange Commission (SEC) rejected calls for a Bitcoin (BTC) exchange-traded fund (ETF).

That news came as a blow to investors, many of whom believe the ETF would open the cryptocurrency industry up to pension funds and other institutional investors. This would create a massive tailwind for cryptos, they say.

So it only follows that a rejection of the Bitcoin ETF should send cryptos tumbling, correct? Well, maybe you can follow that logic. To me, it seems like a dramatic overreaction.

I understand that legitimizing cryptos is important. But.

The post Cryptocurrency News: New Exchanges Could Boost Crypto Liquidity appeared first on Profit Confidential.

More:

Cryptocurrency News: New Exchanges Could Boost Crypto Liquidity

Cryptocurrency News: Bitcoin ETF Rejection, AMD Microchip Sales, and Hedge Funds

Cryptocurrency News
Although cryptocurrency prices were heating up last week (Bitcoin, especially), regulators poured cold water on the rally by rejecting calls for a Bitcoin exchange-traded fund (ETF). This is the second time that the proposal fell on deaf ears. (More on that below.)

Crypto mining ran into similar trouble, as you can see from Advanced Micro Devices, Inc.'s (NASDAQ:AMD) most recent quarterly earnings. However, it wasn't all bad news. Investors should, for instance, be cheering the fact that hedge funds are ramping up their involvement in cryptocurrency markets.

Without further ado, here are those stories in greater detail.
ETF Rejection.

The post Cryptocurrency News: Bitcoin ETF Rejection, AMD Microchip Sales, and Hedge Funds appeared first on Profit Confidential.

See the original post here:

Cryptocurrency News: Bitcoin ETF Rejection, AMD Microchip Sales, and Hedge Funds

Bitcoin Rise: Is the Recent Bitcoin Price Surge a Sign of Things to Come or Another Misdirection?

What You Need to Know About the Bitcoin Price Rise
It wasn't that long ago that Bitcoin (BTC) dominated headlines for its massive growth, with many cryptocurrency millionaires being made. The Bitcoin price surged ever upward and many people thought the gravy train would never stop running—until it did.

Prices crashed, investors abandoned the space, and lots of people lost money. Cut to today and we're seeing another big Bitcoin price surge; is this time any different?

I'm of a mind that investors ought to think twice before jumping back in on Bitcoin.

Bitcoin made waves when it once again crested above $5,000. Considering that it started 2019 around $3,700,.

The post Bitcoin Rise: Is the Recent Bitcoin Price Surge a Sign of Things to Come or Another Misdirection? appeared first on Profit Confidential.

Continued here:

Bitcoin Rise: Is the Recent Bitcoin Price Surge a Sign of Things to Come or Another Misdirection?

Molecular medicine – Wikipedia

Molecular medicine is a broad field, where physical, chemical, biological, bioinformatics and medical techniques are used to describe molecular structures and mechanisms, identify fundamental molecular and genetic errors of disease, and to develop molecular interventions to correct them.[1] The molecular medicine perspective emphasizes cellular and molecular phenomena and interventions rather than the previous conceptual and observational focus on patients and their organs.[2]

In November 1949, with the seminal paper, "Sickle Cell Anemia, a Molecular Disease",[3] in Science magazine, Linus Pauling, Harvey Itano and their collaborators laid the groundwork for establishing the field of molecular medicine.[4] In 1956, Roger J. Williams wrote Biochemical Individuality,[5] a prescient book about genetics, prevention and treatment of disease on a molecular basis, and nutrition which is now variously referred to as individualized medicine[6] and orthomolecular medicine.[7] Another paper in Science by Pauling in 1968,[8] introduced and defined this view of molecular medicine that focuses on natural and nutritional substances used for treatment and prevention.

Published research and progress was slow until the 1970s' "biological revolution" that introduced many new techniques and commercial applications.[9]

Some researchers separate molecular surgery as a compartment of molecular medicine.[10]

Molecular medicine is a new scientific discipline in European universities.[citation needed] Combining contemporary medical studies with the field of biochemistry, it offers a bridge between the two subjects. At present only a handful of universities offer the course to undergraduates. With a degree in this discipline the graduate is able to pursue a career in medical sciences, scientific research, laboratory work and postgraduate medical degrees.

Core subjects are similar to biochemistry courses and typically include gene expression, research methods, proteins, cancer research, immunology, biotechnology and many more. In some universities molecular medicine is combined with another discipline such as chemistry, functioning as an additional study to enrich the undergraduate program.

Read the original post:

Molecular medicine - Wikipedia

Molecular Medicine Conference 2019 | Molecular Diagnostics …

Scientific Sessions Track 1: Molecular Medicine

Molecular medicine is a broad field which deals with the development of diseases at a molecular level and identifies fundamental molecular and genetic errors of disease and to develop molecular interventions to correct them. Molecular structures and mechanisms are described by Physical, chemical, biological, bioinformatics and medical techniques. Disease pathogenesis at the molecular or physiological level may lead to the design of specific tools for disease diagnosis, treatment, or prevention.

By understanding the genes, proteins, and other cellular molecules work molecular medicine develops ways to diagnose and treat disease. Molecular Medicine develops knowledge and skills in cellular and molecular biology.

Molecular diagnostics is a collection of techniques used to analyse an individual's genetic code and to identify biological markers in the genome and proteome. Molecular diagnostics apply molecular biology to see how cell express their genes to medical testing. For any successful application of gene therapy or biologic response modifiers, molecular diagnostics offers a great tool. Molecular diagnostics now provides most laboratory tests in infectious diseases, genetics, and an increasing number in oncology. Molecular diagnostics analyse a person's health at a molecular level by detecting specific sequences in deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) that may be related to disease

Molecular genetics employs methods of both molecular biology and genetics to study the structure, function and interactions among genes at a molecular level.

The study of chromosomes and gene expression of an organism can give an accurate and deep understanding of heredity, genetic variation, and mutations. Molecular Genetics and Genomics cover all areas on the latest research innovations, population genetics, gene function and expression and molecular genetics. Molecular genetics is concerned with the study of your favourite gene, genomics is concerned with studying all the genes. Molecular genomics is a critical component of the expanding database linking alterations of DNA and RNA with the disease, disease prognosis and therapeutic response.

Molecular oncology refers to the chemistry of cancer and tumours at the molecular scale and their development and application on molecularly targeted therapies.

Molecular Oncology studies especially the genetic alterations and their implications. Molecular Oncology focuses on new discoveries, approaches, as well as technical developments in basic, clinical and discovery-driven cancer research. It mainly focuses on advances in the understanding of disease processes leading to human tumour development. Molecular Oncology establishes novel concepts of clear clinical significance in diagnosis, prognosis and prevention strategies.

A biomarker is used as an indicator of the biological state. In routine clinical use Oncology biomarkers actually, make their way. A biological marker points to the presence of a disease, a physiological change, response to treatment, or a psychological condition.

Molecular biomarkers are used for various purposes including disease diagnosis and prognosis and assessment of treatment response. Over the last decade, there has been a significant increase in the number of drug labels containing information on molecular biomarkers. In most of the chronic diseases, biomarkers can confirm a difficult diagnosis or even make it possible in the first place.

Molecular biology is the study of biological activity between biomolecules in the various systems of a cell. It also includes the interactions between DNA, RNA, proteins and their biosynthesis as well as the regulation of these interactions.

Cellular and Molecular Biology majorly study the processes that occur within and between the body's cells. This includes genes, the way cells carry nutrients throughout the body, and how diseases attack healthy cells. The process of replication, transcription and translation of the genetic material are studied under Molecular biology. Cellular biology study cells, including their function, systems, structure and interactions with living organisms. These typically work in medical fields and are often focused on the treatment of disease.

Molecular pathology is the study of molecules within organs, tissues or bodily fluids. Molecular pathology is commonly used in the diagnosis of bone, soft tissue tumours, cancer and infectious diseases. The purpose of molecular pathology is to understand the mechanisms of disease by identifying molecular and pathway alterations. It is considered the heart of modern diagnostics and translational research. Molecular pathology studies and diagnose disease through the examination of genetic and molecular abnormalities. Molecular pathology and biomarkers are used to study molecular and genomic abnormalities in tissues for diagnostic and prognostic purposes. Molecular diagnosis is useful and sometimes necessary as an adjunct for diagnosis especially in morphologically or clinically unusual lesions.

Living things all are alike at the cellular and molecular level. The fundamental similarities between living organisms are explained by evolutionary theory. Major topics in molecular evolution concern the rates and impacts of single nucleotide changes, origins of new genes, the evolution of development, and ways that evolutionary forces influence genomic and phenotypic changes. Some of the key advances are quantitative estimates of both the diversity in populations and of evolutionary relationships, as well as improvements in theoretical understanding. There is an improved understanding of the function of proteins and much better models of the common patterns of development.

Advances in cell and molecular biology studies have revolutionized the diagnosis and treatment of many different diseases. It is considered as a modern Biotechnology concerned with understanding the Genetic Diagnosis, Molecular Diagnosis, Molecular Forensics.

People at the present day are facing serious global challenges in healthcare from emerging and re-emerging diseases. The availability of new sequencing methods, microarrays, microfluidics, biosensors, and biomarker assays has made a shift toward developing diagnostic platforms, which stimulates growth in the field regarding diagnosis, prognosis, and treatment, leading to improved outcomes and greater cost savings.

Much research is being done in foetal whole exome sequencing and is beginning to play a large role in miscarriage testing. With all this research and screening, clinicians and genetic counsellors need to keep abreast of these changes and guidelines in order to effectively care for patients.

The genetic cause of foetal abnormalities detected on ultrasound imaging and in high-risk families can be significantly identified and improved in Foetal diagnostic exome sequencing. Testing based on isolation of foetal cells from maternal blood would provide an attractive alternative to testing of cell-free DNA. An updated implementation of these different approaches will make lively discussion and insight into this field and is headed ways for researchers, test providers, clinicians and clinics to take these developments into consideration.

Point-of-care testing is medical diagnostic testing at the time and place of patient care. In Recent years there are tremendous advances in POCD due to innovations lab-on-a-chip technologies, and complementary technologies. Critical advances in POCD provides directions for future research. Point-of-care allows physicians and medical staff to accurately achieve real-time, lab-quality diagnostic results within minutes rather than hours. The global Point of Care diagnostic tests renders immediate results providing improved patient care in rural areas too. This factor has significantly impacted the market growth.

Clinical diagnostics is defined as diagnosis and treatment of human disease. Clinical diagnostics for a disease can be done by patient's complaints based on signs, symptoms and medical history rather than on laboratory examination or medical imaging. Clinical diagnostics is considered as an ever-changing field of medicine and research. In recent years Clinical diagnostics has become more exciting as advances in new techniques aid in fulfilling the potential of personalized medicine. Clinical research determines the safety and effectiveness of medications, devices, diagnostic products and treatments.

A monoclonal antibody (mAb) is originally produced by a single B-cell. Biosimilars are a lot complicated than small-molecule medicine and generics. In the past few years, monoclonal antibody drugs have dominated the world's largest biopharmaceutical drug sales, and in the coming years, monoclonal antibody drugs will continue to be the main force. Considering the huge profit margins and potential market, the monoclonal antibody-based therapeutics is the hot territory many pharmaceutical companies chases. This session will summarize the market in terms of therapeutic applications, type, and structure of mAbs, dominant companies, manufacturing locations, and emerging markets. These requirements would lead to greater development in the process and tighter quality controls during the production of biosimilar mAbs.

Infectious diseases are caused by pathogenic organisms such as viruses, bacteria, or fungus. Normally harmless but under certain conditions, they can be fatal and can cause death too. They can be spread from one person to another directly or indirectly. Infectious diseases are caused by infection-causing organisms that use the human body for surviving, reproducing and colonizing. These organisms are known as pathogens.

Antibiotics are used to treat bacterial infections;

Antiviral agents treat viral infections;

and

Antifungal agents treat fungal infections.

Next-generation sequencing (NGS) has revolutionised the study of genomics and molecular biology by allowing us to sequence DNA and RNA much more quickly and cheaply than the previously used Sanger sequencing. Next Generation Sequencing (NGS) relies on capillary electrophoresis. NGS although with shorter read lengths and less accuracy reduces the time that genome sequencing projects took with Sanger methods.

Thousands to millions of DNA molecules can be sequenced simultaneously by using Powerful Next Generation Sequencing (NGS) platform. By offering a high throughput option NGS is revolutionizing in fields such as personalized medicine, genetic diseases, and clinical diagnostics.

Immunogenicity is the ability of a particular substance induce a humoral and/or cell-mediated immune responses. An immune response can be potentially elicited by administering any substance into the human body.

Products which increase the potential of anti-drug antibodies include :

Therapeutic antibodies, enzyme therapies, peptides and combination products.

An immune response may also impact a drugs safety and efficacy. Assays should be designed in such a way that they provide sufficient sensitivity and are free from potential risks to the target patient population. By designing assays with these factors, it is possible to gather data about the strength and type of immune response that a drug may produce in humans.

Metagenomics is the study of genetic material recovered from environmental samples. Metagenomics could be an asset of analysis techniques comprising several connected approaches and ways. We tend to anticipate that metagenomics can complement and stimulate analysis on people and their genomes.

Metagenomics represents a brand-new approach in exceedingly genomic analysis. Metagenomic libraries can be screened for novel physiological, metabolic, and genetic options. Though long and labour-intensive, metagenomics is the most powerful environmental approach that provides prospects to get novel genes and novel biomolecules through the expression of genes from an uncultivated and unknown bacterium in a recipient host cell. Metagenomic information ought to contain DNA sequences for all the genes within the microorganism community

Cell therapies and regenerative medication boost the health of patients by repairing, replacing, or by creating broken cells within the body. Some elements of our bodies will repair themselves quite well when injured, while others dont repair in any respect. We cant develop an entire leg or arm; however, some animals will develop or regenerate whole body elements. Stem cells (SC) offer totally different. Despite the promise of embryonic stem cells, in several cases, adult or perhaps vertebrate stem cells give a lot of fascinating approach for clinical applications. Clinical applications in regenerative medication have increased tremendously throughout the last ten years. Regenerative medication revolutionizes the method to improve the health and quality of life by restoring, maintaining or enhancing tissue and functions of organs.

Clinical chemistry is usually involved with analysis of bodily fluids for diagnostic and therapeutic functions. It's an applied style of organic chemistry. There are currently several blood tests and clinical tests with intensive diagnostic capabilities. These are performed on any bodily fluid or plasma. The foremost common specimens tested in clinical chemistry are blood and Serum. Many various tests exist to check glucose, electrolytes, enzymes, hormones, lipids (fats), and proteins. By running tests on these samples, physicians will confirm patient conditions and potential diseases, and recommend a counselled treatment up. Clinical chemistry procedures create precise diagnoses, offer effective treatment choices and monitor a patients response to treatment.

Pharmacogenomics is the study of the gene effect on a persons response to medication. This comparatively new field combines pharmacological medicine and genetics to develop effective, safe medications and doses that may be tailored to a persons genetic makeup. Several medications presently accessible do not work a similar manner for everybody. Adverse drug reactions are a unit of big trouble for hospitalizations. With the data gained from the HGP, researchers are learning variations in genes have an effect on the bodys response to medications.

The field of pharmacogenomics continues to be in its infancy. Its use is presently quite restricted, however new approaches are in clinical trials. In future, pharmacogenomics can permit the tailored medication to treat health issues, as well as disorders, Alzheimer sickness, cancer, HIV/AIDS, and asthma.

DNA sequencing is the method of sequencing the base pairs of a DNA (As, Ts, Cs, and Gs). Sequencing a whole organisms DNA is a huge task. It needs breaking the DNA into several smaller items, sequencing the items, and collection of these sequences into one long "consensus."

These bases give the information on genotype and also the phenotype. Nucleotides aren't the sole determinants of phenotypes but are essential to their information. Every individual and organism feature a specific ester base sequence. DNA sequencing additionally underpins pharmacogenomics. This can be a comparatively new field that is leading to an individualized medication. Over a hundred and forty medication approved by the FDA currently by pharmacogenomic data in their labelling.

Translational medicine is defined as an interdisciplinary branch of the biomedical field. By using a highly collaborative approach Translational medicine is growing in biomedical research discipline and aims to expedite the discovery of new diagnostic tools and treatments. Within public health, translational medicine is focused on ensuring proven strategies for disease treatment and prevention. Translational medicine aims to improve human health and longevity by determining the relevance to human disease of novel discoveries in the biological sciences. Translational medicine is enhancing the efficiency of biomedical discovery and application. There are many compelling reasons to find cost-effective solutions to health care delivery.

Integrative Molecular Medicine covers novel findings in molecular, biological, and biomedicine research. The broad spectrum of Integrative Molecular Medicine includes rare and common disorders from diagnosis to treatment.

Molecular drugs strive to know traditional body functioning and illness pathological process at the molecular level which can enable researchers and physician-scientists to use that information within the style of specific molecular tools for illness identification, treatment, and prognosis. Integrative Molecular drugs (imMed) offers a scientific setting, which mixes basic and clinical analysis and offers a broad vary of advanced opportunities.

Medical doctors, patients, and health care providers consider the prevention of genetic diseases as an essential tool to improve the general health status of the population and the proportion of people suffering from genetics and genomics disease will increase by 65.2% by 2025. The top institutions researching in the related studies have been funded with 100 Billion Dollar worldwide. According to recent statistics, genetic diseases worldwide will double between 2012 and 2025. The market value of Molecular Medicine is $24 billion in 2015 and is expected to reach more than $100 billion by 2025.

Molecular Diagnostics Equipment market is influencing the

Molecular Diagnostics Equipment market is growing in -

witnessed growth in the -

followed by Molecular Diagnostics Equipment market in -

and the Middle East and Africa -

In 2015, the global molecular diagnostics market size was valued at USD 6,451.5 million and is anticipated to grow. In 2018, infectious diseases account for the largest share of the global molecular diagnostics market. Greater accuracy, portability, cost-effectiveness and Technological advancements enable molecular diagnostics to significantly drive the market.

Over the forecast period, the rising prevalence of infectious diseases and hospital-acquired infections are expected to drive market growth. Rise in cardiovascular, neurological, and genetic disorders is also expected to fuel market growth. Governments and different organizations Increase in funding for clinical studies in the molecular diagnosis space boost the market growth.

The hospitals and academic laboratories segment are expected to account for the largest share of the market in 2018.

The growth of the UAE diagnostic market can be attributed to the high prevalence of chronic and infectious diseases. WHO estimates of all deaths worldwide Chronic diseases account for approximately 60 %. Chronic diseases such as cancer, cardiovascular diseases, diabetes, and chronic respiratory diseases are responsible for 12%, 40%, 5%, and 5% of mortality in the United Arab Emirates. There has been a paradigm shift from traditional diagnostics to a new generation diagnostic, that works at the gene level. The inclusion of Advanced technologies such as genetic testing, molecular diagnostics, polymerase chain reaction (PCR), and next-generation sequencing (NGS) made it possible.

The major market players in the UAE molecular diagnostics market are :

The competition among manufacturers is increasing, with the increasing number of companies.

Genomics 2018

ME Conferenceshosted10thInternational Conference on Genomics & Molecular BiologyduringMay 21-23, 2018atBarcelona, Spainbased on the theme Advanced Approaches In Genomics and Molecular Biology.

Active participation and generous response was received from the Organizing Committee Members, scientists, researchers, as well as experts from Non-government organizations, and students from diverse groups who made this conference as one of the most successful and productive events in 2018 fromME Conferences.

The conference was marked with several workshops, multiple sessions, Keynote presentations, panel discussions and Poster sessions. We received active participation from scientists, young and brilliant researchers, business delegates and talented student communities representing more than 35 countries, who have driven this event into the path of success.

The conference was initiated with a warm welcome note by Honorable guests and the Keynote forum.The proceedings went through interactive sessions and panel discussions headed byhonorable ModeratorDr.Laila Alves Nahum, Ren Rachou Research Center, Brazilfor the conference.

The conference proceedings were carried out through various Scientific-sessions and plenary lectures, of which the following Speakers were highlighted asKeynote speakers:

Single point mutation of a gene creates mirror-image animals in freshwater gastropod:Reiko Kuroda, Tokyo University of Science, Japan

Evolutionary genomics to improve functional prediction of parasite genes and proteins:Laila Alves Nahum, Ren Rachou Research Center, Brazil

Big data in noncoding RNA and precision medicine:Runsheng Chen, Institute of Biophysics - CAS, China

Treatment of landfi ll leachate via advanced biological treatment technology:Ling Tau Chuan, University of Malaya, Malaysia

Biophysical signaling, systems biology and carcinogenesis:Sarah S Knox, West Virginia University School of Public Health USA

How does nucleoid complexity affect cell dimensions during the division process in bacillary bacteria: Arieh Zaritsky, Ben-Gurion University of the Negev, Israel

ME Conferenceshas taken the privilege of felicitating Genomics-2018 Organizing Committee, Keynote Speakers who supported for the success of this event.ME Conferences, on behalf of the Organizing Committee, congratulates the Best Poster awardees for their outstanding performance in the field of Genomics & Pharmacogenomics and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavors.

Poster Judging was done byDr.Arieh Zaritsky, Ben-Gurion University of the Negev, Israel

We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums. We sincerely thank theOrganizing Committee Membersfor their gracious presence, support, and assistance towards the success of Genomics-2018.

With the unique feedback from the conference,ME Conferenceswould like to announce the commencement of the "4th International Conference on Molecular Medicine and Diagnostics"duringJuly 15-16, 2019 in Abu Dhabi, UAE.

For More details visit:https://molecularmedicine.conferenceseries.com/

Read more:

Molecular Medicine Conference 2019 | Molecular Diagnostics ...

Master of Science (MSc) in Molecular Medicine – Trondheim …

The field of molecular medicine is often referred to as "tomorrow's medicine". It aims to provide a molecular understanding of how normal cellular processes change, fail or are destroyed by disease. The purpose of the MSc programme is to develop knowledge and skills in cellular and molecular biology. These have applications in both research and practical clinical work, and will contribute to an increased understanding of processes, diagnostics and treatment of diseases.

The application deadline for for applicants from non-EU/non-EEA students is 1 December. The application deadline for students from EU/EEA countries is 1 March. The application for student from Nordic countries is 15 April. You submit your application electronically.

The MSc in Molecular Medicine qualifies graduates for a wide range of careers, including practical clinical work and technical executive positions in hospital laboratories, and positions in pharmaceuticals and MedTech/BioTech companies.

The MSc is a two-year, full-time programme starting in the autumn semester. There are two main components: a master's thesis worth 60 credits, and theoretical and methodological courses totalling a further 60 credits.

Contact one of our student counsellors if you have any questions about the MSc in Molecular Medicine. Email: studie@ikom.ntnu.no/ Telephone: +47 72 82 07 00

Go here to read the rest:

Master of Science (MSc) in Molecular Medicine - Trondheim ...

Home | EMBO Molecular Medicine

Rare diseases, which affect over 350million people worldwide and frequently go undiagnosed or misdiagnosed for years, suffer from sparse and dispersed medical knowledge leading to even rarer approved and effective therapeutic options for patients. A vast, unmet need for research and investment to advance diagnostic capabilities and therapeutic development must be confronted, despite the myriad of challenges faced. Several fundamental shifts are changing the landscape of rare diseases research and development, particularly with the application and extension of results to common diseases and the advancement of personalized medicine initiatives. Collaborative strategies that pool resources and knowledge are vital, including team science, research networks, novel funding models, shared knowledge platforms, and innovative regulatory frameworks. Importantly, patients are also increasingly involved as research partners and funders, pushing for open science and transparency, and breaking down data silos and geographical borders, often enabled by online platforms accessible from across the globe. The International Rare Diseases Research Consortium (IRDiRC), established in 2011, has been working diligently to unify stakeholders (e.g., funding bodies, companies, umbrella patient advocacy groups, researchers, and experts) to seek and drive solutions that aim to accelerate diagnosis and therapeutic development for rare diseases worldwide. Further and future advances will depend on continued collaborations and cooperation among stakeholders, working hand in hand with patients, and exponentially improving research and development efficiency. Critically, engagement with stakeholders from underrepresented populations and lessdeveloped countries must be prioritized, to enable all people living with a rare disease to receive an accurate diagnosis, care, and therapy.

Rare diseases: further and future advances for diagnostic capabilities and therapeutic development will depend on continued collaborations and cooperation among stakeholders, working handinhand with patients, and exponentially improving research and development efficiency.

EMBO Mol Med (2019) e10486

This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Go here to read the rest:

Home | EMBO Molecular Medicine

Department of Molecular Genetics … – College of Medicine

Work alongside a distinguished group of researchers in Gene Expression, RNA Processing, DNA replication, Genomics, Gene Therapy, Molecular Basis of Disease, and the Mechanisms of Viral and Bacterial Pathogenesis.

MGM plays a central role in several interdisciplinary research programs in the HSC. Affiliated centers include the UF Genetics Institute, the Powell Gene Therapy Center, the Center for Epigenetics, and the University of Florida Brain Institute.

Read the original:

Department of Molecular Genetics ... - College of Medicine

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

New! Nuclear Medicine Online Review Course

Take SNMMIs new online nuclear medicine review course. Updated for 2019, and covering the most essential topics in nuclear medicineyou'll gain the level of expertise you need to ace your exam! AMA PRA Category 1 credits available. Learn More

Access synchronized slides, audio and embedded video from 100 of the most popular sessions from SNMMIs 2018 Annual Meeting.Learn More

2018 Virtual Meeting Specialty PackagesPackages include:Cardiovascular, General Clinical Specialties, Neurosciences, Oncology and Therapy, and Technologist

The new Radiation Safety+ Review and Essentials program provides a comprehensive overview of all aspects of radiation safety for nuclear medicine technologists preparing to take the NMTCBs Radiation Safety Certification Examination.Learn More

CT+ Review and Essentials provides you with the comprehensive didactic education you need to succeed, whether you're looking to buildyour general CT knowledge, or preparing to sit for the ARRT (CT) and/or NMTCB (CT) exam(s).Learn More

SNMMI/ACNM MRI Case Reviews: AbdominalSNMMI and ACNM have partnered to bring you the first-ever set of online MRI teaching modules as an introduction to interpreting MRI.Learn More

Mid-Winter Meeting CT Case ReviewsThis offering provides a comprehensiveCT Case Reviewfor nuclear medicine professionals. Review and interpret up to 100 CT studies.Learn More

Annual Meeting CT/MRI Case ReviewsRecorded at the Annual Meeting, this online offering provides the opportunity to review and interpret 52 CT studies and 48 MRI case studies.Learn More

Free Journal SAM/CE accessis available exclusively for SNMMI Members. Take advantage of this great benefit and meet your certification requirements.Learn more

The PET Online Review Workshop is designed to prepare technologists for the NMTCB's PET Exam.Learn More

Visit link:

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

When the Large Hadron Collider Turns on, It May Trap Dark Matter

Scientists have a new plan to try and spot dark matter by searching for particular particles once the Large Hadron Collider's upgrades are complete.

Eyes Peeled

When the Large Hadron Collider (LHC) turns back on and starts smashing particles again sometime in 2021, it may also point us in the direction of dark matter.

For years, scientists have been trying and failing to spot the invisible stuff that makes up the majority of matter in the universe. But now researchers have a new target: a comparatively heavy and long-lived particle that may be produced by the high-energy collisions at the LHC.

The particle is thought by some physicists to occasionally interact with dark matter — giving scientists a new lead toward spotting the elusive material.

Dangling Particle

Research published this month in Physical Review Letters describes how systems that have already been put in place at the LHC could detect these long-lived particles, which are named as such because they travel slower and last longer than other particles generated by LHC experiments.

The time difference is on the scale of nanoseconds, according to a University of Chicago press release — something that the LHC was already able to detect and will be even better at once upgrades are completed.

“If the particle is there, we just have to find a way to dig it out,” University of Chicago physicist LianTao Wang said in the press release. “Usually, the key is finding the question to ask.”

READ MORE: Scientists invent way to trap mysterious ‘dark world’ particle at Large Hadron Collider [University of Chicago newsroom via Phys.org]

More on dark matter: An Oxford Scientist May Have Solved the Mystery of Dark Matter

The post When the Large Hadron Collider Turns on, It May Trap Dark Matter appeared first on Futurism.

See the article here:

When the Large Hadron Collider Turns on, It May Trap Dark Matter

Astronomers Finally Found the Universe’s First Type of Molecule

Scientists finally detect helium hydride, a combination of helium and hydrogen, thought to be the first molecule to form in the universe.

Happy Hunting

Based on scientists’ calculations, the first molecule to ever form from stray atoms in the universe was likely helium hydride, a combination of helium and hydrogen.

For decades, physicists have hunted the universe for the elusive molecule. And now an international team of researchers say they’ve finally found it — thereby confirming the presumed first step in the universe’s chemistry.

No Doubt

In a study published in the journal Nature Wednesday, the researchers describe how they used NASA’s Stratospheric Observatory for Infrared Astronomy (SOFIA), the world’s largest airborne observatory, to detect helium hydride in a planetary nebula about 3,000 light-years away from Earth.

“It was so exciting to be there, seeing helium hydride for the first time in the data,” researcher Rolf Guesten said in a news release. “This brings a long search to a happy ending and eliminates doubts about our understanding of the underlying chemistry of the early universe.”

READ MORE: The Universe’s First Type of Molecule Is Found at Last [NASA]

More on the early universe: Scientists Now Know When the First Stars Formed in the Universe

The post Astronomers Finally Found the Universe’s First Type of Molecule appeared first on Futurism.

See more here:

Astronomers Finally Found the Universe’s First Type of Molecule

India Blew up a Satellite. Now A “Space Fence” Is Tracking Its Debris

When India blew up a satellite, it introduced a lot of debris into orbit. Lockheed Martin's experimental Space Fence is keeping an eye on it.

Explosive Demonstration

Last month, India demonstrated its capabilities as a spacefaring nation and drew international criticism when it used a missile to blew up one of its own satellites.

The launch happened to coincide with Lockheed Martin’s test run of a new space monitoring technology called the Space Fence, which can detect and track any unregistered objects orbiting the Earth. According to Space News, that was a stroke of luck that could mitigate damage to people and equipment in space.

Picket Fence

The satellite explosion essentially turned the satellite into a cloud of space debris, which could in the future collide with other satellites, scientific instruments, or astronauts in orbit around the Earth — remember “Gravity”?

“We happened to be up during an endurance test and we were very excited to see that the system performed nominally,” Matthew Hughes, Lockheed Martin business development manager, told Space News. “Space fence is all about the ability to identify break ups, maneuvers, closely spaced objects, proximity operations, new foreign launches.”

While Space Fence isn’t an actual blockade in space, it can at least help officials prepare for and plan around collisions.

READ MORE: Indian anti-satellite test proves early test for Space Fence [Space News]

More on India’s Satellite: NASA: When India Blew up a Satellite, it Endangered Astronauts

The post India Blew up a Satellite. Now A “Space Fence” Is Tracking Its Debris appeared first on Futurism.

See the article here:

India Blew up a Satellite. Now A “Space Fence” Is Tracking Its Debris

Expert: AI-Generated Music Is A “Total Legal Clusterf*ck”

The legal industry isn't ready for AI-generated music, leading to all sorts of new questions about copyrights in the age of creative machines.

AI-Generated Music

If you train a music-generating artificial intelligence exclusively on tracks by Beyoncé, do you owe the pop star a cut of any resulting songs’ profits? And is it even legal to use copyrighted songs to train an AI in the first place?

Those are just a couple of the questions The Verge poses in a fascinating new story about AI-generated music published Wednesday. And while the publication consulted numerous experts from the music, tech, and legal industries for the story, the input of one person in particular — Jonathan Bailey, CTO of audio tech company iZotope — seemed to most concisely sum up the issue.

“I won’t mince words,” he told The Verge. “This is a total legal clusterfuck.”

Imitation Game

Despite the U.S. Copyright Office bringing up the potential problems that could arise from computer songwriters way back in 1965, U.S. copyright law has yet to nail down exactly who owns what when a computer is involved in the creative process, according to The Verge.

As it stands, the Beyoncé-trained AI could crank out an entire album of “Lemonade”-esque tracks, and as long as none of them sounded too much like any specific Beyoncé song, the AI-generated music wouldn’t be infringing on her copyrights — and the AI’s creator wouldn’t legally owe the artist a penny, lawyer Meredith Rose told The Verge.

Less clear is the use of copyrighted songs to train an AI. Several of The Verge’s sources said there isn’t a straightforward answer as to whether buying a song grants a person the right to then use it to train a machine learning system.

Clock’s Ticking

Of course, programmers have yet to come anywhere near creating AIs capable of autonomously churning out hit songs in the key of Bey — or anyone else for that matter — but that doesn’t mean they won’t be able to one day.

“It’s like the future of self-driving cars,” media-focused venture capitalist Leonard Brody told Fortune in October. “Level 1 is an artist using a machine to assist them. Level 2 is where the music is crafted by a machine but performed by a human. Level 3 is where the whole thing is machines.”

We’ve already seen several examples of those first two levels — tech-forward songstress Taryn Southern shared songwriting credits with AI on her “I AM AI” album, released in September, and that same month, Iranian composer Ash Koosha released an album on which he sang songs composed by AI-powered software.

If Brody’s prediction is correct, the next step will be AIs creating music by themselves — and if we’re already in the midst of a “legal clusterfuck,” who knows what sort of legislative nightmare that will be?

READ MORE: WE’VE BEEN WARNED ABOUT AI AND MUSIC FOR OVER 50 YEARS, BUT NO ONE’S PREPARED [The Verge]

More on AI songwriters: This Musician Created an AI to Write Songs for Him, and They’re Pretty Strange

The post Expert: AI-Generated Music Is A “Total Legal Clusterf*ck” appeared first on Futurism.

Read more:

Expert: AI-Generated Music Is A “Total Legal Clusterf*ck”

The Mueller Report Confirms We’re Living in a Cyberpunk Dystopia

The Mueller Report, heavily redacted, describes a number of high-tech Russian operations designed to undermine and sway the 2016 Presidential election.

Harm to Ongoing Matter

When the Justice Department released a heavily-redacted version of the Mueller Report Thursday, the conversation quickly devolved into partisan bickering.

Only time will tell what the report means for the Trump administration. But what’s immediately clear is that concepts that were once restricted to fictional cyberpunk dystopias — from government hackers to botnet propaganda networks — are now mainstream enough to influence international politics.

Black Boxes

The readable text of the report details how Russia used social media, hackers, and other sophisticated techniques to try and sway the 2016 U.S. Presidential election in favor of Trump — efforts that reached millions of Americans and recruited others to actively spread their propaganda before and after the election.

Russians working for an organization called the Internet Research Agency created accounts on Twitter and Facebook, through which they reached millions — including many members of the Trump Administration, Trump’s sons, and Trump himself — while sharing pro-Trump and anti-Clinton messages, memes, and images.

Personal Privacy

Meanwhile, other Russian operatives were taking a more direct approach — by hacking into Democratic Party servers, releasing sensitive information though sock puppet personas like “DCLeaks” and “Guccifer” and giving stolen data to WikiLeaks. Just to make the whole thing a little more “Shadowrun,” they funded the operation by mining Bitcoin.

In the long view, the report might be less memorable for its specific claims than as a blueprint for the future of information warfare — and the strange ways technology can be used to manipulate and control populations.

READ MORE: Report On The Investigation Into Russian Interference In The 2016 Presidential Election [CNN]

More on Mueller: Everything You Need to Know From Mark Zuckerberg’s Congressional Testimony: Day 1

The post The Mueller Report Confirms We’re Living in a Cyberpunk Dystopia appeared first on Futurism.

See the original post:

The Mueller Report Confirms We’re Living in a Cyberpunk Dystopia

Climate Change Could Cause Fukushima-Style Meltdowns in the US

Almost every active nuclear reactor in the U.S. is unprepared for flooding and storm surge caused by climate change; industry groups chose not to act.

Unprepared

Most nuclear power plants in the United States are not prepared for the increase in flooding and severe weather that climate change will soon bring.

Of the roughly 60 operational plants in the U.S., 90 percent have at least one design flaw that will render them susceptible to flood damage and storm surge, according to Bloomberg. If preventative measures aren’t taken and upgrades made, then the U.S. may face radiation leaks like the 2011 disaster at the Fukushima Daiichi Nuclear Power Plant in Japan.

Meltdown

Speaking to Bloomberg, the Nuclear Energy Institute’s Matthew Wald argued that such a meltdown was incredibly unlikely in the U.S. thanks to emergency equipment installed in some reactors.

“There is a perennial problem in any high-tech industry deciding how safe is safe enough,” Wald said, “The civilian nuclear power industry exceeds the NRC-required safety margin by a substantial amount.”

But often, individual reactors and nuclear industry organizations are allowed to set those standards themselves. Bloomberg reports that these groups were allowed to estimate not only their own reactors’ resilience in the face of climate change, but also just how bad they expected the effects of climate change to get in their area.

Oversight

With that lack of regulation, it’s no surprise that the nuclear energy industry cleared the hurdles — the industry is basically bragging about how it slam-dunked on a children’s basketball hoop.

“Any work that was done following Fukushima is for naught because the commission rejected any binding requirement to use that work,” Gregory Jaczko, who was chairman of the U.S. Nuclear Regulatory Commission in 2011 during the Fukushima meltdown, told Bloomberg. “It’s like studying the safety of seat belts and then not making automakers put them in a car.”

READ MORE: U.S. Nuclear Power Plants Weren’t Built for Climate Change [Bloomberg]

More on nuclear power: See the Centaur-Like Robot Designed to Handle Nuclear Reactors

The post Climate Change Could Cause Fukushima-Style Meltdowns in the US appeared first on Futurism.

Originally posted here:

Climate Change Could Cause Fukushima-Style Meltdowns in the US

Denver Is Voting on Whether to Decriminalize Psychedelic Mushrooms

Denver, Colorado, may soon decriminalize the personal use of psilocybin-containing mushrooms, making it the first place in the U.S. to consider doing so.

Trip to the Polls

Denver, Colorado may become the first city in the U.S. to decriminalize shrooms — if a new initiative gets voted through.

It’s only one city, but the vote suggests that Americans are coming around to a more progressive view on recreational — and potentially therapeutic — psychoactive drugs.

Changing Minds

If passed, Initiative 301 would decriminalize personal use and possession of mushrooms containing the psychoactive compound psilocybin. But wouldn’t legalize the growth or distribution of the shrooms, according to Vox — so it’d fall short of the full-throated legalization of marijuana that Colorado embraced in 2014.

Decriminalization of psychedelic shrooms could help Denver save time and money. Per Vox, other decriminalized areas like Portugal saw drops in drug use and drug-related deaths, suggesting that telling police to stop pursuing drug use could benefit society across the board.

READ MORE: Denver may become the first US city to decriminalize psychedelic mushrooms [Vox]

More on Psilocybin: Psychedelic Mushrooms Can Boost Creativity and Empathy For a Week

The post Denver Is Voting on Whether to Decriminalize Psychedelic Mushrooms appeared first on Futurism.

Read the rest here:

Denver Is Voting on Whether to Decriminalize Psychedelic Mushrooms

This Space Roomba Could Clean the ISS While Astronauts Sleep

GermFalcon, a company specializing in airplane sanitizing tech, developed a kind of space Roomba that can blast sterilising UV rays at the walls of the ISS.

Worst Job Ever

Wiping down the inside of the International Space Station is an arduous task.

But luckily, thanks to a private company specializing in airplane sanitizing tech called GermFalcon, astronauts aboard the ISS might be able to skip that chore in the future: an autonomous, Roomba-style space cleaner called GermRover could one day blast the walls with powerful sterilizing UV rays to kill any harmful microbes.

“UV disinfection has been shown to decrease hospital infection rates, so we expect to replicate those results in space,” Elliot Kreitenberg, developer of the robot, told New Scientist.

Filthy Space Station

Futurism has previously reported on how conditions can get nasty on board the ISS.

Research published earlier this month suggests that the ISS is teeming with bacterial and fungal colonies. Some of these bacteria were even found to be antibiotic-resistant as well, compounding the problem.

NASA is currently looking into trialing the GermRover. GermFalcon is working on a prototype it will reveal at the Aerospace Medicine Association conference in Las Vegas next month, according to the New Scientist.

READ MORE: Zero-gravity robot cleaner could automatically sterilise the ISS [New Scientist]

More on germs on the ISS: The International Space Station is Teeming With Germs

The post This Space Roomba Could Clean the ISS While Astronauts Sleep appeared first on Futurism.

Excerpt from:

This Space Roomba Could Clean the ISS While Astronauts Sleep